Real-Life Pharmacokinetics of rFVIII-Fc and rFIX-Fc
Main Authors: | Marissa J.M. Traets, Kathelijn Fischer, Nanda Uitslager, Paul R. van der Valk, Idske C.L. Kremer Hovinga, Lize F.D. van Vulpen, Roger E.G. Schutgens |
---|---|
Format: | Article |
Language: | English |
Published: |
Georg Thieme Verlag KG
2020-10-01
|
Series: | TH Open |
Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1718416 |
Similar Items
-
Extended Half-life rFVIII for the Treatment of Hemophilia A: Drugs Consumption and Patients’ Perspective
by: Daniela Paola Roggeri, et al.
Published: (2020-06-01) -
Recently approved recombinant factor VIII (rFVIII) for the replacement treatment in patients with hemophilia A in Italy
by: Daniela Paola Roggeri, et al.
Published: (2017-10-01) -
Transient transfection of serum-free suspension HEK 293 cell culture for efficient production of human rFVIII
by: Swiech Kamilla, et al.
Published: (2011-11-01) -
Critical Review of the Pivotal Studies of Four rFVIII Products for the Treatment of Hemophilia A Patients: The Role of Octocog Alfa
by: Matteo Nicola Dario Di Minno, et al.
Published: (2020-04-01) -
Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
by: Mancuso ME, et al.
Published: (2014-03-01)